Cargando…

Identification of Selective CYP3A7 and CYP3A4 Substrates and Inhibitors Using a High-Throughput Screening Platform

Cytochrome P450 (CYP) 3A7 is one of the major xenobiotic metabolizing enzymes in human embryonic, fetal, and newborn liver. CYP3A7 expression has also been observed in a subset of the adult population, including pregnant women, as well as in various cancer patients. The characterization of CYP3A7 is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kabir, Md, Padilha, Elias C., Shah, Pranav, Huang, Ruili, Sakamuru, Srilatha, Gonzalez, Eric, Ye, Lin, Hu, Xin, Henderson, Mark J., Xia, Menghang, Xu, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283723/ https://www.ncbi.nlm.nih.gov/pubmed/35847040 http://dx.doi.org/10.3389/fphar.2022.899536

Ejemplares similares

Use of Tox21 Screening Data to Evaluate the COVID-19 Drug Candidates for Their Potential Toxic Effects and Related Pathways
por: Sakamuru, Srilatha, et al.
Publicado: (2022)

Identification of Angiogenesis Inhibitors Using a Co-culture Cell Model in a High-Content and High-Throughput Screening Platform
por: Li, Shuaizhang, et al.
Publicado: (2017)

Pregnancy related hormones increase CYP3A mediated buprenorphine metabolism in human hepatocytes: a comparison to CYP3A substrates nifedipine and midazolam
por: Fashe, Muluneh M., et al.
Publicado: (2023)

Effect of CYP3A4(∗)1G and CYP3A5(∗)3 Polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects
por: Liu, Shuaibing, et al.
Publicado: (2017)

Identification and Analysis of CYP7A1, CYP17A1, CYP20A1, CYP27A1 and CYP51A1 in Cynomolgus Macaques
por: UNO, Yasuhiro, et al.
Publicado: (2014)

Frog intestinal perfusion to evaluate drug permeability: application to p-gp and cyp3a4 substrates
por: Yerasi, Neelima, et al.
Publicado: (2015)

Developmental Pharmacogenetics of CYP2D6 in Chinese Children: Loratadine as a Substrate Drug
por: Li, Qian, et al.
Publicado: (2021)

Enzymatic Activities of CYP3A4 Allelic Variants on Quinine 3-Hydroxylation In Vitro
por: Zhou, Xiao-Yang, et al.
Publicado: (2019)

The Dynamic Effect of Non-CYP3A4-Metabolized and CYP3A4-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction
por: Shi, Hong Ting, et al.
Publicado: (2021)

Genetic variation in the 3′-UTR of CYP1A2, CYP2B6, CYP2D6, CYP3A4, NR1I2, and UGT2B7: potential effects on regulation by microRNA and pharmacogenomics relevance
por: Swart, Marelize, et al.
Publicado: (2014)

High-Throughput Screening to Predict Chemical-Assay Interference
por: Borrel, Alexandre, et al.
Publicado: (2020)

Regulation of X-Ray Irradiation on the Activity and Expression Levels of CYP1A2 and CYP2E1 in Rats
por: Li, Xiang-Yang, et al.
Publicado: (2020)

Effect of CYP3A4, CYP3A5, MDR1 and POR Genetic Polymorphisms in Immunosuppressive Treatment in Chilean Kidney Transplanted Patients
por: Contreras-Castillo, Stephania, et al.
Publicado: (2021)

Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates
por: Saiz-Rodríguez, Miriam, et al.
Publicado: (2020)

The Modulatory Role of CYP3A4 in Dictamnine-Induced Hepatotoxicity
por: Li, Zhuo-Qing, et al.
Publicado: (2018)

Influence of FMO3 and CYP3A4 Polymorphisms on the Pharmacokinetics of Teneligliptin in Humans
por: Park, Jin-Woo, et al.
Publicado: (2021)

Evaluation of Selected CYP51A1 Polymorphisms in View of Interactions with Substrate and Redox Partner
por: Režen, Tadeja, et al.
Publicado: (2017)

Prevalence and Accuracy of Information on CYP2D6, CYP2C19, and CYP2C9 Related Substrate and Inhibitor Co-Prescriptions in the General Population: A Cross‐Sectional Descriptive Study as Part of the PharmLines Initiative
por: Bahar, Muh. Akbar, et al.
Publicado: (2020)

Identification of Compounds That Inhibit Estrogen-Related Receptor Alpha Signaling Using High-Throughput Screening Assays
por: Lynch, Caitlin, et al.
Publicado: (2019)

Effects of CYP3A4*22 and CYP3A5 on clinical outcome in patients treated with ticagrelor for ST-segment elevation myocardial infarction: POPular Genetics sub-study
por: Azzahhafi, Jaouad, et al.
Publicado: (2022)

Adverse Drug Reactions of Antihypertensives and CYP3A5*3 Polymorphism Among Chronic Kidney Disease Patients
por: Lee, Fei Yee, et al.
Publicado: (2022)

The impact of CYP2D6*41 on CYP2D6 enzyme activity using phenotyping methods in urine, plasma, and saliva
por: Jin, Ye, et al.
Publicado: (2022)

The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses
por: Kee, Ping Siu, et al.
Publicado: (2023)

A frequent CYP2D6 variant promotes skipping of exon 3 and reduces CYP2D6 protein expression in human liver samples
por: Collins, Joseph M., et al.
Publicado: (2023)

CYP2D6 Phenotyping Using Urine, Plasma, and Saliva Metabolic Ratios to Assess the Impact of CYP2D6(∗)10 on Interindividual Variation in a Chinese Population
por: Chen, Rui, et al.
Publicado: (2017)

Borneol influences the pharmacokinetics of florfenicol through regulation of cytochrome P450 1A2 (CYP1A2), CYP2C11, CYP3A1, and multidrug resistance 1 (MDR1) mRNA expression levels in rats
por: LI, Xuting, et al.
Publicado: (2021)

Effect of Genetic Variability in the CYP4F2, CYP4F11, and CYP4F12 Genes on Liver mRNA Levels and Warfarin Response
por: Zhang, J. E., et al.
Publicado: (2017)

CYP2C8 and CYP2C9 mRNA expression profile in the human fetus
por: Johansson, Maria, et al.
Publicado: (2014)

Characterization of the genetic variation present in CYP3A4 in three South African populations
por: Drögemöller, Britt, et al.
Publicado: (2013)

The Influence of CYP3A4 Genetic Polymorphism and Proton Pump Inhibitors on Osimertinib Metabolism
por: Gao, Nanyong, et al.
Publicado: (2022)

Functional evaluation of cyclosporine metabolism by CYP3A4 variants and potential drug interactions
por: Kong, Qihui, et al.
Publicado: (2023)

Mining of high throughput screening database reveals AP-1 and autophagy pathways as potential targets for COVID-19 therapeutics
por: Zhu, Hu, et al.
Publicado: (2021)

CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Nifedipine in Chinese Renal Transplant Patients
por: Yang, Yilei, et al.
Publicado: (2021)

Why We Need to Take a Closer Look at Genetic Contributions to CYP3A Activity
por: Zhai, Qinglian, et al.
Publicado: (2022)

Metabolomics-based discovery of XHP as a CYP3A4 inhibitor against pancreatic cancer
por: Yang, Yuting, et al.
Publicado: (2023)

Characterization of complex structural variation in the CYP2D6-CYP2D7-CYP2D8 gene loci using single-molecule long-read sequencing
por: Turner, Amy J., et al.
Publicado: (2023)

Altered CYP19A1 and CYP3A4 Activities Due to Mutations A115V, T142A, Q153R and P284L in the Human P450 Oxidoreductase
por: Udhane, Sameer S., et al.
Publicado: (2017)

CYP3A4 and CYP3A5 genotyping by Pyrosequencing
por: Garsa, Adam A, et al.
Publicado: (2005)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
por: Sanchez Spitman, A. B., et al.
Publicado: (2017)

CYP2D7 Sequence Variation Interferes with TaqMan CYP2D6(*)15 and (*)35 Genotyping
por: Riffel, Amanda K., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_o5j4efk788096k1erh8p8u0abj